Identification of CD8+ T-cell Epitopes from VEGFR2 for Angiogenesis Inhibition

Strategic Insights -

Scientists have identified two CD8+ T-cell epitopes, VILTNPISM and FSNSTNDILI, from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. These epitopes, discovered by researchers at the U.S. National Cancer Institute, were found to be effective in reducing angiogenesis and inhibiting tumor growth in mouse models. This discovery provides a novel approach to immunotherapy for cancer treatment.

Key Takeaways:

  • Researchers identified two CD8+ T-cell epitopes, VILTNPISM and FSNSTNDILI, from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.
  • These epitopes were naturally processed and target endothelial cells, which play a crucial role in tumor-associated angiogenesis.
  • Immunization with these peptides reduced angiogenesis and inhibited tumor growth in mouse models.
  • This approach may provide a novel immunotherapy for inhibition of tumor growth, either alone or in combination with other anti-angiogenesis agents.
  • Researchers at the U.S. National Cancer Institute discovered the epitopes, and the study was published in the Journal of Immunotherapy.
  • The study highlights the potential of CD8+ T-cell epitopes in targeting angiogenesis for cancer treatment.

Statistics:

  • Two CD8+ T-cell epitopes, VILTNPISM and FSNSTNDILI, were identified from mouse VEGFR2.
  • Immunization with these peptides reduced angiogenesis by [no specific percentage mentioned in the source].
  • Tumor growth was inhibited in mouse models by [no specific percentage mentioned in the source].
  • The study was published in the Journal of Immunotherapy (Vol. 29, Issue 1, 2006).

Sources:

  • "Identification of -2D[superscript]b-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth." Journal of Immunotherapy, 2006;29(1):32-40.
  • National Cancer Institute, Vaccine Branch, Center for Cancer Research, National Institutes of Health.